← All trials
NCT06258850
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2024
- Primary completion
- Jun 30, 2027
- Completion date
- Dec 31, 2027
- First posted
- Feb 14, 2024
- Last posted
- Feb 14, 2024
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Institut Hospital del Mar d'Investigacions MèdiquesLead sponsor
- University of CantabriaCollaborator
- University of BarcelonaCollaborator
- University of ValenciaCollaborator
- University of ValenciaCollaborator
- Universidad Autonoma de BarcelonaCollaborator
- Universidad Autonoma de BarcelonaOfficial
- University of SevilleCollaborator
- Institut Hospital del Mar d'Investigacions MèdiquesSponsor investigator
- Universidad Complutense de MadridCollaborator
- Hospital Universitario Ramon y CajalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.